On May 22, 2026, Joshua S. Lev, who serves as both the Chief Financial Officer and Interim President of electroCore, Inc. (NASDAQ:ECOR), reported the disposition of company common stock valued at $19,500.
According to documentation filed with the Securities and Exchange Commission, Mr. Lev executed the sale by disposing of 3,000 shares of electroCore common stock. The selling price for these shares was established at $6.50 per share. Sources confirm that this specific transaction was undertaken solely to fulfill tax withholding requirements generated upon the vesting and settlement of previously issued Restricted Stock Units (RSUs).
This reported insider activity takes place amid varied market signals concerning electroCore. The company's stock has experienced a significant appreciation, having surged 42% over the preceding six months and currently trading at $6.67.
Analysis provided by InvestingPro suggests that, despite the recent price movement, the stock may be undervalued at its current levels. Analysts have consequently established price targets for the company ranging between $12 and $26.
Following the sale of shares in this transaction, Mr. Lev's direct holdings increased to 91,556 shares. This total holding comprises 9,556 shares of common stock and an additional 82,000 shares of common stock that are issuable under previously granted RSUs. These latter shares remain subject to various vesting schedules and ongoing continuous service conditions.
Beyond the specific insider transaction, electroCore has released several operational updates demonstrating both financial strength and medical progress. For instance, Electrocore LLC announced a record-high quarterly revenue for the first quarter of 2026 (Q1 2026). The company achieved net sales totaling $9.6 million in that period.
This reported revenue figure marks a substantial increase of 43% when compared to the corresponding period in the previous year. However, this strong top-line growth was accompanied by a GAAP net loss of $5.3 million for Q1 2026. This level of loss represents an escalation from the $3.9 million net loss recorded during Q1 2025.
Furthermore, medical advancements were highlighted through a clinical study published in JAMA Network Open. The research focused on the use of electroCore’s modified Quell device specifically for treating fibromyalgia. The trial included 384 participants and concentrated on evaluating the device's effectiveness when utilized alongside standard outpatient physical therapy.
The design of this clinical trial was notable due to its cluster randomized structure, a methodological element that contributes robustness to the resulting findings. These combined developments illustrate electroCore’s continued focus across both enhancing financial performance metrics and advancing medical innovation in its core areas.
Risks
- The increase in GAAP net loss to $5.3 million in Q1 2026 compared to $3.9 million in Q1 2025 suggests potential challenges in cost management or operational scaling.
- While the stock has surged 42% over six months, analysts' price targets range significantly ($12 to $26), indicating differing views on future valuation and market stability.
- The reliance on continued RSU vesting schedules and continuous service conditions for a significant portion of Mr. Lev’s holdings introduces operational dependency.
More from Insider Trading